<DOC>
	<DOC>NCT00987207</DOC>
	<brief_summary>Primary objective: To evaluate the efficacy of the cyclosporin A administration to induce a cardioprotection during the valvular surgery.</brief_summary>
	<brief_title>Pharmacological Postconditioning During the Aortic Valvular Surgery</brief_title>
	<detailed_description />
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Male or females, scheduled for an aortic valvular surgery; 18 years of age or older. Combined valvular and coronary surgery; Significant coronary artery stenosis (upper than 70%); Left ventricular dysfunction (ejection fraction &lt; 40%); Emergency surgery and/or infectious endocarditis; Known cyclosporin hypersensitivity; History of known recent immunosuppression (&lt; 6 months): cancer, lymphoma, positive serology for HIV, hepatitis; Renal insufficiency (creatininaemia &gt; 150 Âµmol/l); Hepatic insufficiency (prothrombin time &lt; 50%); Uncontrolled arterial hypertension defined by a systolic arterial pressure &gt; 180 mm Hg; Women of child bearing potential, who are pregnant or not under efficient contraception; Patients treated with nicorandil, sulfonylurea or rosuvastatine; Patients under judicial control.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Postconditioning</keyword>
	<keyword>cyclosporine A</keyword>
	<keyword>myocardial ischemia</keyword>
	<keyword>cardiac surgery</keyword>
	<keyword>aortic valvulopathy</keyword>
</DOC>